Maintenance practices, component engineering and international market notes — for QC, R&D and stability teams and the manufacturers who serve them.
The SBA is expanding its network to 12 regional clusters, connecting small businesses with supply chains, financing and procurement opportunities, including two new biotechnology hubs.
Eduardo Bravim discusses Advanced Life Sciences’ expanding technology division, the specialized B2B vision behind Depth Stride, and the investment, development and testing required before its launch.
Eduardo Bravim examines how artificial intelligence can increase productivity and strengthen decision-making without replacing professional judgment, accountability, leadership or human experience. This English adaptation was originally published by CRA-SP — Conselho Regional de Administração de São Paulo.
Anvisa has already approved six synthetic semaglutide pens since the patent expired in March 2026. Eduardo Rocha Bravim explains why the next dispute will be decided inside the plant — production capacity, process control, raw material qualification, robust analytical methods, batch-to-batch consistency and a supply chain able to hold strict specifications at scale.
Manufacturing, logistics, suppliers and planning all influence medicine availability. In this interview, Eduardo Rocha Bravim explains why a disruption can begin long before the production line — in a critical input, a logistics restriction, a regulatory change or a geopolitical conflict — and how supplier qualification, predictive analytics and real-time integration between supply chain, production, quality control and regulatory affairs reduce the risk of shortages.
Escalating trade disputes have put global supply chain security back at the centre of the debate — and the pharmaceutical sector is among the most exposed. With China accounting for 73.7% of the active pharmaceutical ingredients imported by India between 2024 and 2025, Eduardo Rocha Bravim examines how tariffs affect raw materials, analytical instrumentation, quality control, regulatory qualification and operational planning, and why resilience must be engineered rather than improvised.
Microsoft, Meta, Oracle, Amazon and Alphabet have disclosed roughly US$1.16 trillion in future commitments tied largely to data centers and AI infrastructure — almost four times what already appears as lease obligations on their balance sheets. What this capital cycle means for drug discovery, regulatory operations, GMP manufacturing, AI validation, data sovereignty and the rise of specialized pharmaceutical platforms.
Eduardo Bravim explains how ORBIT was created to integrate customer relationships, commercial opportunities, products, technical services, documentation, business intelligence and artificial intelligence into a single corporate operating system.
The U.S. Food and Drug Administration has approved EZPLAZ™ Freeze Dried Plasma (FDP), developed by Teleflex — the first freeze-dried plasma product ever licensed in the United States. The approval marks a significant advancement in emergency medicine, trauma care, military healthcare and disaster response.
Europe, North America and Oceania have all faced shortages of antibiotics, chronic disease treatments, oncology drugs and mental health medicines. Behind every product on the shelf lies a highly complex chain — from active pharmaceutical ingredients and manufacturing to quality control, regulatory requirements, international logistics and distribution — where any disruption can compromise supply. Eduardo Rocha Bravim discusses how planning, supplier diversification, demand forecasting, digital traceability and closer coordination between industry, distributors and pharmacies can make the chain more resilient and keep treatments available to patients.
For many years, sustainability initiatives in the pharmaceutical industry were primarily associated with environmental responsibility. Today, the scenario has changed. Reducing waste has become a strategic objective that directly supports product quality, operational efficiency, regulatory compliance, and business performance. Modern pharmaceutical manufacturers are increasingly investing in digital technologies, process monitoring, predictive maintenance, and data-driven decision-making to minimize material losses while maintaining the highest quality standards. Beyond reducing costs, waste prevention contributes to more resilient manufacturing processes, improved supply chain performance, and stronger compliance with Good Manufacturing Practices (GMP). As regulatory expectations continue to evolve, sustainability should no longer be viewed as a separate initiative. It is becoming an integral part of quality management and operational excellence across the pharmaceutical industry.
ANVISA issues a public warning about the growing use of AI-generated fake videos and images of healthcare professionals promoting medicines and dietary supplements — and the Advanced Life Sciences perspective on responsible AI in Life Sciences.
The U.S. Food and Drug Administration has approved Lipfendra® (enlicitide), the first oral PCSK9 inhibitor for reducing LDL cholesterol — a milestone in cardiovascular care and pharmaceutical innovation.
Advanced Life Sciences becomes BIKAI Technology's distributor for the United States, bringing Japanese-engineered deuterium lamps and high-performance light sources to HPLC, UHPLC and UV-Vis laboratories nationwide.
Advanced Life Sciences becomes the official U.S. representative of Raytor Instruments, expanding its portfolio of intelligent and automated analytical instrumentation for pharmaceutical, biotechnology, academic and analytical laboratories.
Eduardo Bravim introduces Pharma Intelligence — a platform under development that integrates AI, knowledge management, compliance, qualification, asset management and training into a single digital ecosystem for pharmaceutical operations.
An opinion article by Eduardo Bravim exploring how pharmaceutical markets across the Americas differ in competition, technology, global strategy, operational efficiency and international expansion.
Exclusive interview with Eduardo Bravim discussing the manufacturing, regulatory, and scalability challenges of personalized gene and cell therapies. Originally published by Guairá News.
The pharmaceutical industry is undergoing a significant technological transformation driven by increasingly complex global regulatory requirements, digitalization, advanced analytical technologies, automation, data integrity expectations, and innovation demands.
A comparative analysis of the regulatory frameworks, market structures, pricing dynamics and innovation ecosystems that shape pharmaceutical industries across the Americas.
How Raman spectroscopy is reshaping pharmaceutical quality control — from real-time process monitoring aligned with FDA PAT guidelines to integration with MES/LIMS platforms, GxP compliance, and continuous manufacturing strategies.
How the new international guidance from EMA and FDA is shaping the future of AI in regulated pharmaceutical environments — governance, human oversight, data integrity and lifecycle management.
How pharmaceutical and life sciences organizations are adapting to new global regulatory, digitalization, data integrity and analytical technology requirements.
Preventive maintenance is the most cost-effective lever for instrument uptime, method reproducibility and audit readiness in analytical laboratories.
Practical indicators — intensity drift, baseline noise and lamp hours — that signal when a D2 lamp has reached the end of its useful life.
Kit-based maintenance shortens engineer time, ensures part compatibility and produces audit-ready documentation by default.
A practical comparison of OEM and compatible spare parts — including performance, traceability and total cost of ownership.
Managing acquisition, qualification, maintenance, upgrades and retirement to maximize the useful life and ROI of analytical instruments.
What international manufacturers need to consider when entering scientific equipment markets across the Americas and Europe.
